X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services
January 26, 2021
X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.
- Buyers
- X-Chem, Inc.
- Targets
- IntelliSyn, AviSyn
- Sellers
- Shareholders of IntelliSyn and AviSyn
- Platforms
- X-Chem, Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
X-Chem Acquires Glamorous AI and ComInnex
October 29, 2021
Biotechnology
X-Chem, a GHO Capital-backed leader in DNA-encoded library (DEL) technology, has acquired AI drug-discovery specialist Glamorous AI and Budapest-based synthetic chemistry services provider ComInnex. The deals expand X-Chem’s machine-learning capabilities and synthetic chemistry capacity, broadening its global footprint and accelerating small-molecule discovery services for biopharma clients.
-
NuChem Sciences Acquires IniXium
October 31, 2022
Biotechnology
Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.
-
GHO Capital Acquires X‑Chem, Inc.
June 3, 2020
Biotechnology
GHO Capital Partners LLP has acquired X‑Chem, Inc., the Waltham-based provider of DNA‑Encoded Library (DEL) small‑molecule discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman. GHO will invest in X‑Chem's DEL platform and support international growth while appointing co‑founder Matt Clark as CEO.
-
Sygnature Discovery Acquires NuChem Sciences
August 1, 2023
Biotechnology
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
-
eMolecules Acquires Synple Chem AG
September 24, 2024
Biotechnology
eMolecules, a San Diego-based provider of a chemical compound search-and-fulfillment platform and a portfolio company of Avista Healthcare Partners, has acquired Synple Chem AG, an automated chemical synthesis systems and services provider headquartered near Zurich, Switzerland. The acquisition adds Synple's automation technology and a virtual compound library of more than 7 trillion tractable compounds to eMolecules' existing offering, expanding its capabilities as a one-stop shop for compound procurement, management and automation for drug discovery customers.
-
AbbVie Acquires Syndesi Therapeutics
March 1, 2022
Biotechnology
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.